Later, several clinical trials demonstrated that advanced NSCLC patients with the EGFR mutation who had been receiving first- and second-generation EGFR-TKI treatment experienced longer progression-free survival (PFS) and fewer adverse effects than those patients receiving platinum-based chemotherapy [5,6,7]. Here, EGFR is linked to non-small cell lung carcinoma.